Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Skyrizi (risankizumab) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, the treatment of active psoriatic arthritis in adults, and the treatment of moderately to severely active Crohn's disease in adults.
• This summary is based on the review of 31 systematic review(s)/meta-analysis(es). ^[1-31]
• Psoriatic Arthritis (PsA): Risankizumab significantly improved ACR20 response rates (RR 1.760, 95% CI 1.568-1.977, P<0.001) and MDA response rates (RR 1.827, 95% CI 1.048-3.184, P<0.05) compared to placebo. Additionally, it improved health-related quality of life metrics including SF-36, HAQ-DI, and FACIT-F scores.
• Crohn’s Disease (CD): Risankizumab was effective in inducing clinical remission, with RR 0.66 (95% CI 0.52-0.85) in biologic-naïve and RR 0.74 (95% CI 0.67-0.82) in biologic-experienced patients. In a real-world study, 70% of CD patients achieved clinical remission by week 12, with 63% achieving corticosteroid-free remission.
• Psoriasis: Risankizumab demonstrated high efficacy in achieving PASI 75, 90, and 100 scores, with sustained responses over 44-60 weeks. Network meta-analyses showed its PASI 90 and PASI 100 rates were comparable to or superior to other biologics such as ixekizumab, brodalumab, and guselkumab.
• In Psoriatic Arthritis (PsA), risankizumab showed no significant differences in serious adverse events (SAE) and serious treatment-emergent adverse events (STEAE) when compared to placebo, with similar overall adverse event (AE) incidence between the two groups.
• For Crohn's Disease (CD), risankizumab demonstrated a favorable safety profile, with most adverse effects being mild and a decreased risk of serious adverse events compared to placebo in both induction and maintenance trials.
• In Psoriasis, risankizumab had a low incidence of adverse events, with no significant differences in serious adverse events (SAE) compared to placebo. Long-term studies indicated the lowest rates of adverse events leading to treatment discontinuation and serious adverse events.
• There is no population types or subgroups information available in the reviewed studies.